Compare MQ & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MQ | VIR |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2021 | 2019 |
| Metric | MQ | VIR |
|---|---|---|
| Price | $4.43 | $10.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $5.36 | ★ $19.43 |
| AVG Volume (30 Days) | ★ 2.6M | 1.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,884,000.00 | $68,556,000.00 |
| Revenue This Year | $16.89 | $270.22 |
| Revenue Next Year | $16.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.25 | N/A |
| 52 Week Low | $3.70 | $4.16 |
| 52 Week High | $7.04 | $11.66 |
| Indicator | MQ | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 61.13 | 52.60 |
| Support Level | $4.37 | $8.47 |
| Resistance Level | $4.50 | $10.29 |
| Average True Range (ATR) | 0.14 | 0.55 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 84.62 | 38.85 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.